Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis (VALOR-CKD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03710291
Recruitment Status : Recruiting
First Posted : October 18, 2018
Last Update Posted : December 9, 2020
Sponsor:
Information provided by (Responsible Party):
Tricida, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the effect of TRC101 on the progression of chronic kidney disease (CKD) and to evaluate the safety profile of TRC101 in CKD patients with metabolic acidosis.

Condition or disease Intervention/treatment Phase
Metabolic Acidosis Chronic Kidney Disease Drug: TRC101 Drug: Placebo Phase 3

Detailed Description:
This is a randomized, double-blind, placebo-controlled trial. Eligible subjects will be randomized in a 1:1 ratio to TRC101 or placebo. The primary endpoint of the study will be progression of renal disease, defined by time to first occurrence of any event in the composite endpoint consisting of a confirmed ≥ 40% reduction in eGFR, end-stage renal disease (ESRD), and renal death. The study will terminate when the independent blinded Clinical Endpoint Adjudication Committee has positively adjudicated the targeted number of primary efficacy endpoint events. The maximum duration of follow-up for a randomized subject is anticipated to be approximately 6 years.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis
Actual Study Start Date : November 20, 2018
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: TRC101 Drug: TRC101
Oral, non-absorbed, polymeric hydrochloric acid binder
Other Name: Veverimer
Placebo Comparator: Placebo Drug: Placebo
Placebo comparator


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Progression of chronic kidney disease [ Time Frame: Through study completion, up to approximately 6 years. ]
    Time to first occurrence of: a confirmed ≥40% reduction in eGFR; ESRD; renal death.


Secondary Outcome Measures :
  1. Death (all-cause), ESRD or a confirmed ≥50% reduction in eGFR [ Time Frame: Through study completion, up to approximately 6 years. ]
    Time to first occurrence of: death (all-cause); ESRD; a confirmed ≥50% reduction in eGFR.

  2. Physical functioning (subjective) [ Time Frame: 18 months after randomization. ]
    Kidney Disease Quality of Life Physical Functioning Survey.

  3. Physical functioning (objective) [ Time Frame: 18 months after randomization. ]
    Repeated chair stand test.

  4. ESRD or renal death [ Time Frame: Through study completion, up to approximately 6 years. ]
    Time to ESRD or renal death.

  5. Primary outcome measure OR cardiovascular death [ Time Frame: Through study completion, up to approximately 6 years. ]
    Time to first occurrence of: a confirmed ≥40% reduction in eGFR; ESRD; renal death; cardiovascular death.

  6. Serum creatinine [ Time Frame: Through study completion, up to approximately 6 years. ]
    Time to first occurrence of a confirmed doubling of serum creatinine.

  7. ≥50% reduction in eGFR [ Time Frame: Through study completion, up to approximately 6 years. ]
    Time to first occurrence of a confirmed ≥50% reduction in eGFR.

  8. ≥40% reduction in eGFR [ Time Frame: Through study completion, up to approximately 6 years. ]
    Time to first occurrence of a confirmed ≥40% reduction in eGFR.

  9. All-cause hospitalization [ Time Frame: Through study completion, up to approximately 6 years. ]
    Frequency of all-cause hospitalization.

  10. Cardiovascular death [ Time Frame: Through study completion, up to approximately 6 years. ]
    Time to cardiovascular death.

  11. All-cause mortality [ Time Frame: Through study completion, up to approximately 6 years. ]
    Time to all-cause mortality.


Other Outcome Measures:
  1. Safety of TRC101 [ Time Frame: Through study completion, up to approximately 6 years. ]
    Frequency, intensity, and relationship to study drug of adverse events and serious adverse events.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Estimated glomerular filtration rate (eGFR) 20 - 40 mL/min/1.73m^2.
  • Serum bicarbonate 12 - 20 mEq/L.
  • On maximum tolerated dose of ACE inhibitor and/or ARB.

Exclusion Criteria:

  • Acute metabolic acidosis.
  • Anticipated dialysis or kidney transplant within 6 months.
  • Recent acute kidney injury.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03710291


Contacts
Layout table for location contacts
Contact: Clinical Operations 415-988-5120 valor@tricida.com

Locations
Show Show 361 study locations
Sponsors and Collaborators
Tricida, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Tricida, Inc.
ClinicalTrials.gov Identifier: NCT03710291    
Other Study ID Numbers: TRCA-303
2018-001303-36 ( EudraCT Number )
First Posted: October 18, 2018    Key Record Dates
Last Update Posted: December 9, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tricida, Inc.:
serum bicarbonate
renal outcomes
TRC101
eGFR
veverimer
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Acidosis
Urologic Diseases
 Renal Insufficiency
Acid-Base Imbalance
Metabolic Diseases